A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Registration Number
- NCT03978520
- Lead Sponsor
- AbbVie
- Brief Summary
The main objective of this study was to evaluate the safety and efficacy of elsubrutinib, upadacitinib (UPA), and ABBV-599 (elsubrutinib/upadacitinib) High Dose and Low Dose combinations vs placebo for the treatment of signs and symptoms of Systemic Lupus Erythematosus (SLE) in participants with moderately to severely active SLE and to define doses for further development.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 341
-
Participant has clinical diagnosis of Systemic Lupus Erythematosus (SLE) at least 24 weeks prior to Screening, meeting at least 4 of the 11 revised Criteria for Classification of SLE according to the 1997 Update of the 1982 American College of Rheumatology (ACR) OR meeting at least 4 of the 2012 SLICC classification criteria, including at least 1 clinical criterion and 1 immunologic criterion.
-
At Screening, must have at least one of the following:
- antinuclear antibody (ANA)+ (titer ≥ 1:80)
- anti-dsDNA+
- anti-Smith+
-
SLEDAI-2K (SLE Disease Activity Index) ≥ 6 despite background therapy as reported and independently adjudicated (clinical score ≥ 4, excluding lupus headache and/or organic brain syndrome) at Screening:
- If 4 points of the required entry points are for arthritis, there must also be a minimum of 3 tender and 3 swollen joints.
- If participant has rash and Principal Investigator (PI) considers it to be attributable to SLE, participant must consent to skin photograph collection for adjudication.
- Score must be re-confirmed at the Baseline visit.
-
Physician's Global Assessment (PhGA) ≥ 1 during screening period.
-
Must be on background treatment, stable for 30 days prior to Baseline and throughout the study with antimalarial(s), prednisone (or prednisone equivalent) (≤ 20 mg), azathioprine (≤ 150 mg), mycophenolate (<2 g), leflunomide (≤ 20 mg), cyclosporine, tacrolimus, and/or methotrexate (MTX) (≤ 20 mg).
- No combinations of the above with immunomodulators other than prednisone (or equivalents) and antimalarials.
- Participant using intravenous (IV) or intramuscular (IM) corticosteroids greater than or equal to a 40 mg prednisone-equivalent bolus within 30 days of planned randomization.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Elsubrutinib placebo/upadacitinib placebo Placebo for elsubrutinib Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 48 weeks Elsubrutinib placebo/upadacitinib placebo Placebo for upadacitinib Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 48 weeks ABBV-599 High Dose (Elsubrutinib 60 mg/upadacitinib 30 mg) Elsubrutinib 60 mg elsubrutinib capsule once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks ABBV-599 High Dose (Elsubrutinib 60 mg/upadacitinib 30 mg) Upadacitinib 60 mg elsubrutinib capsule once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks Elsubrutinib placebo/upadacitinib 30 mg Placebo for elsubrutinib Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks Elsubrutinib placebo/upadacitinib 30 mg Upadacitinib Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks ABBV-599 Low Dose (Elsubrutinib 60 mg/upadacitinib 15 mg) Elsubrutinib 60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; 15 mg upadacitinib film-coated tablet once a day by mouth for up to 24 weeks ABBV-599 Low Dose (Elsubrutinib 60 mg/upadacitinib 15 mg) Upadacitinib 60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; 15 mg upadacitinib film-coated tablet once a day by mouth for up to 24 weeks Elsubrutinib 60 mg/upadacitinib placebo Elsubrutinib 60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 24 weeks Elsubrutinib 60 mg/upadacitinib placebo Placebo for upadacitinib 60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 24 weeks
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24 Baseline, Week 24 SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline:
* ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score
* No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\])
* No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA) Response at Week 24 Baseline, Week 24 BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment \[PhGA\], \< 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.
Percentage of Participants Achieving SLE Responder Index (SRI)-4 at Week 24 Baseline, Week 24 SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline:
* ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score
* No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\])
* No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 24 Baseline, Week 24 LLDAS is a state of low disease activity based on Systemic Lupus Erythematosus Disease Activity Index 2000 score (SLEDAI-2K score ≤4 excluding SLEDAI-2K activity in major organ systems), absence of SLE disease activity in major organ systems and new disease activity, Physician's Global Assessment (PhGA ≤1), and concomitant medication usage (steroid dose ≤7.5 mg QD and toleration of immunosuppressive drugs at standard maintenance doses).
Change From Baseline in Daily Prednisone Dose at Week 24 From Baseline to Week 24 Participants' current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented.
Number of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI Flare Index Through Week 24 From Baseline to Week 24 The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.
Trial Locations
- Locations (160)
Medvin Clinical Research /ID# 211996
🇺🇸Tujunga, California, United States
Arizona Arthritis & Rheumatology Research, PLLC /ID# 214522
🇺🇸Mesa, Arizona, United States
Shanghai Changhai Hospital /ID# 211819
🇨🇳Shanghai, Shanghai, China
Millennium Research /ID# 219099
🇺🇸Ormond Beach, Florida, United States
Tomakomai City Hospital /ID# 214234
🇯🇵Tomakomai-shi, Hokkaido, Japan
Vital Medical Center Orvosi es Fogaszati Kozpont /ID# 212796
🇭🇺Veszprém, Veszprem, Hungary
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz /ID# 216971
🇭🇺Gyula, Hungary
Azienda Ospedaliera Universitaria Friuli Centrale/Presidio Ospedaliero Universit /ID# 211858
🇮🇹Udine, Italy
Hopital Pitie Salpetriere /ID# 211831
🇫🇷Paris, France
AP-HP - Hôpital Bicêtre /ID# 211968
🇫🇷Le Kremlin Bicetre, France
NHO Nagoya Medical Center /ID# 213974
🇯🇵Nagoya-shi, Aichi, Japan
Griffith University /ID# 223543
🇦🇺Southport, Queensland, Australia
Universitaetsklinikum Duesseldorf /ID# 212408
🇩🇪Düsseldorf, Nordrhein-Westfalen, Germany
Healthy Medical Center SAS /ID# 211899
🇨🇴Zipaquira, Cundinamarca, Colombia
St. Josephs Health Care Centre /ID# 212331
🇨🇦London, Ontario, Canada
Fukushima Medical University Hospital /ID# 213913
🇯🇵Fukushima-shi, Fukushima, Japan
Kumamoto Shinto General Hospital /ID# 215347
🇯🇵Kumamoto-shi, Kumamoto, Japan
CHU Strasbourg - Hopital Civil /ID# 211981
🇫🇷Strasbourg cedex, France
Debreceni Egyetem Klinikai Kozpont /ID# 212042
🇭🇺Debrecen, Hajdu-Bihar, Hungary
Saitama Medical Center /ID# 213687
🇯🇵Kawagoe-shi, Saitama, Japan
Inha University Hospital /ID# 211691
🇰🇷Incheon, Korea, Republic of
Ajou University Hospital /ID# 211692
🇰🇷Suwon, Gyeonggido, Korea, Republic of
Centrum Medyczne Pratia Warszawa /ID# 218176
🇵🇱Warsaw, Mazowieckie, Poland
Universitair Medisch Centrum Utrecht /ID# 214415
🇳🇱Utrecht, Netherlands
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 211988
🇩🇪Berlin, Germany
ASST Gaetano Pini/Presidio Ospedaliero Pini /ID# 215063
🇮🇹Milan, Italy
Hospital of the University of Occupational and Environmental Health, Japan /ID# 217548
🇯🇵Kitakyushu-shi, Fukuoka, Japan
Hospital Universitario 12 de Octubre /ID# 211757
🇪🇸Madrid, Spain
Orszagos Reumatologiai es Fizioterapias Intezet /ID# 211827
🇭🇺Budapest, Hungary
CHU Bordeaux - Hopital Pellegrin /ID# 211832
🇫🇷Bordeaux, France
Nagano Red Cross Hospital /ID# 214572
🇯🇵Nagano-shi, Nagano, Japan
Ortopedyczno-Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi /ID# 212483
🇵🇱Poznan, Wielkopolskie, Poland
Manchester University NHS Foundation Trust /ID# 211838
🇬🇧Manchester, United Kingdom
Kita-harima Medical Center /ID# 215474
🇯🇵Ono-shi, Hyogo, Japan
Shinshu University Hospital /ID# 213853
🇯🇵Matsumoto-shi, Nagano, Japan
Seoul National University Hospital /ID# 211740
🇰🇷Seoul, Korea, Republic of
Chonnam National University Hospital /ID# 211695
🇰🇷Gwangju, Korea, Republic of
National Hospital Organization Asahikawa Medical Center /ID# 213846
🇯🇵Asahikawa-shi, Hokkaido, Japan
Hospital Universitario Basurto /ID# 212722
🇪🇸Bilbao, Vizcaya, Spain
Hospital Universitario de Galdakao /ID# 212803
🇪🇸Galdakao, Vizcaya, Spain
HUA - Txagorritxu /ID# 212520
🇪🇸Vitoria, Alava, Spain
WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 212482
🇵🇱Wroclaw, Dolnoslaskie, Poland
Hospital Universitario A Coruna - CHUAC /ID# 211719
🇪🇸A Coruna, Spain
Consorci Corporacio Sanitaria Parc Tauli Sabadell /ID# 212145
🇪🇸Sabadell, Barcelona, Spain
GCM Medical Group PSC /ID# 211251
🇵🇷San Juan, Puerto Rico
Waikato Hospital /ID# 213505
🇳🇿Hamilton, Waikato, New Zealand
LeJenue Research Associates /ID# 212327
🇺🇸Miami, Florida, United States
Ohio State University - Wexner Medical Center /ID# 211636
🇺🇸Columbus, Ohio, United States
Allegheny Health Network Research Institute /ID# 211607
🇺🇸Pittsburgh, Pennsylvania, United States
Accurate Clinical Management /ID# 213571
🇺🇸Houston, Texas, United States
Toronto Western Hospital /ID# 213336
🇨🇦Toronto, Ontario, Canada
Morales Vargas Centro de Investigacion S.C. /ID# 212946
🇲🇽Leon, Guanajuato, Mexico
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 212674
🇩🇪Kiel, Schleswig-Holstein, Germany
Jiangsu Province Hospital /ID# 211818
🇨🇳Nanjing, Jiangsu, China
Anhui Provincial Hospital /ID# 211812
🇨🇳Hefei, Anhui, China
Xiangya Hospital Central South University /ID# 212919
🇨🇳Changsha, Hunan, China
People's Hospital of Xinjiang /ID# 211821
🇨🇳Urumqi, China
Huashan Hospital, Fudan University /ID# 213976
🇨🇳Shanghai, Shanghai, China
Preventive Care Sas /Id# 211896
🇨🇴Chia, Cundinamarca, Colombia
CHRU Lille - Hopital Claude Huriez /ID# 211829
🇫🇷Lille, Hauts-de-France, France
Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 211895
🇨🇴Bogota, Cundinamarca, Colombia
Centro de Alta Especialidad en Reumatología e Investigación del Potosí, SC /ID# 212737
🇲🇽San Luis Potosí, San Luis Potosi, Mexico
Taichung Veterans General Hospital /ID# 211957
🇨🇳Taichung, Taiwan
Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant Anna /ID# 211861
🇮🇹Cona, Ferrara, Italy
Taipei Medical University Hospital /ID# 221600
🇨🇳Taipei City, Taiwan
Taipei Veterans General Hosp /ID# 212216
🇨🇳Taipei City, Taiwan
Centro Integral de Reumatologia del Caribe Circaribe SAS /ID# 211894
🇨🇴Barranquilla, Atlantico, Colombia
Clinica Universitaria Bolivari /ID# 211897
🇨🇴Medellin, Colombia
Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 212195
🇮🇹Rome, Lazio, Italy
National Taiwan University Hospital /ID# 211752
🇨🇳Taipei City, Taiwan
Keio University Hospital /ID# 216347
🇯🇵Shinjuku-ku, Tokyo, Japan
RM Pharma Specialists S.A de C.V. /ID# 211879
🇲🇽Mexico City, Ciudad De Mexico, Mexico
Medical Care & Research SA de CV /ID# 212682
🇲🇽Mérida, Yucatan, Mexico
China Medical University Hospital /ID# 212179
🇨🇳Taichung City, Taiwan
CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 211875
🇲🇽Mexico City, Ciudad De Mexico, Mexico
Centro Integral en Reumatologia S.A de C.V /ID# 211876
🇲🇽Guadalajara, Jalisco, Mexico
Linkou Chang Gung Memorial Hospital /ID# 211751
🇨🇳Taoyuan City, Taiwan
Guys and St Thomas NHS Foundation Trust /ID# 211931
🇬🇧London, London, City Of, United Kingdom
Chukyo Hospital /ID# 222625
🇯🇵Nagoya-shi, Aichi, Japan
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 212770
🇩🇪Dresden, Germany
Hospital Universitario Virgen de Valme /ID# 212721
🇪🇸Sevilla, Spain
Arthritis and Rheumatism Associates /ID# 211411
🇺🇸Jonesboro, Arkansas, United States
Wallace Rheumatic Studies Center, LLC /ID# 211600
🇺🇸Beverly Hills, California, United States
Valerius Medical Group & Research Center /ID# 211599
🇺🇸Los Alamitos, California, United States
The Lundquist Institute at Harbor-UCLA Medical Center /ID# 213402
🇺🇸Torrance, California, United States
Inland Rheum Clin Trials Inc. /ID# 213617
🇺🇸Upland, California, United States
Medstar Health Research Institute /ID# 213335
🇺🇸Washington, District of Columbia, United States
Arthritis & Rheumatic Disease Specialties /ID# 214052
🇺🇸Aventura, Florida, United States
Ctr Arthritis & Rheumatic Dise /ID# 212326
🇺🇸Miami, Florida, United States
West Broward Rheumatology Associates /ID# 211881
🇺🇸Tamarac, Florida, United States
Affinity Clinical Research /ID# 211496
🇺🇸Oak Brook, Illinois, United States
Deerbrook Medical Associates /ID# 212251
🇺🇸Vernon Hills, Illinois, United States
IRIS Research and Development, LLC /ID# 213053
🇺🇸Plantation, Florida, United States
Qualmedica Research, LLC /ID# 214765
🇺🇸Evansville, Indiana, United States
University of Iowa Hospitals and Clinics /ID# 215246
🇺🇸Iowa City, Iowa, United States
The Center for Rheumatology and Bone Research /ID# 211610
🇺🇸Wheaton, Maryland, United States
Beth Israel Deaconess Medical Center /ID# 212321
🇺🇸Boston, Massachusetts, United States
June DO, PC /ID# 211674
🇺🇸Lansing, Michigan, United States
West County Rheumatology /ID# 225051
🇺🇸Saint Louis, Missouri, United States
NYU Langone Orthopedic Center /ID# 213620
🇺🇸New York, New York, United States
NYU Langone Ambulatory Care Brooklyn Heights /ID# 211548
🇺🇸Brooklyn, New York, United States
Univ TN Health Sciences Ctr /ID# 212177
🇺🇸Memphis, Tennessee, United States
Premier Rheumatology of Oklahoma /ID# 213850
🇺🇸Tulsa, Oklahoma, United States
STAT Research, Inc. /ID# 211404
🇺🇸Vandalia, Ohio, United States
Dr. Ramesh Gupta /ID# 213381
🇺🇸Memphis, Tennessee, United States
West Texas Clinical Research /ID# 211529
🇺🇸Lubbock, Texas, United States
Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich /ID# 221685
🇦🇷Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina
SW Rheumatology Res. LLC /ID# 211520
🇺🇸Mesquite, Texas, United States
Carilion Clinic /ID# 213500
🇺🇸Roanoke, Virginia, United States
Trinity Universal Research Associates - Carrollton /ID# 211527
🇺🇸Carrollton, Texas, United States
CER Instituto Medico /ID# 222757
🇦🇷Quilmes, Buenos Aires, Argentina
Virginia Mason Medical Center /ID# 211457
🇺🇸Seattle, Washington, United States
Rheumatology and Pulmonary Clinic /ID# 211398
🇺🇸Beckley, West Virginia, United States
Hospital Interzonal General de Agudos General Jose de San Martin /ID# 211679
🇦🇷La Plata, Buenos Aires, Argentina
Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 211634
🇦🇷Rosario, Santa Fe, Argentina
Centro de Investigaciones Medicas Tucuman /ID# 212714
🇦🇷San Miguel de Tucuman, Tucuman, Argentina
Emeritus Research Sydney /ID# 222983
🇦🇺Botany, New South Wales, Australia
Aprillus Asistencia e Investigacion /ID# 211630
🇦🇷Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina
Royal North Shore Hospital /ID# 222982
🇦🇺St Leonards, New South Wales, Australia
Instituto CAICI S.R.L /ID# 211633
🇦🇷Rosario, Santa Fe, Argentina
Hospital Cordoba /ID# 212200
🇦🇷Cordoba, Argentina
Investigaciones Clinicas Tucuman /ID# 211942
🇦🇷San Miguel de Tucuman, Tucuman, Argentina
Rheumatology Research Unit Sunshine Coast /ID# 211902
🇦🇺Maroochydore, Queensland, Australia
Royal Brisbane and Women's Hospital /ID# 212667
🇦🇺Herston, Queensland, Australia
The Queen Elizabeth Hospital /ID# 211901
🇦🇺Woodville South, South Australia, Australia
Monash Medical Centre /ID# 212313
🇦🇺Clayton, Victoria, Australia
St Vincent's Hospital Melbourne /ID# 212311
🇦🇺Fitzroy Melbourne, Victoria, Australia
Emeritus Research /ID# 211903
🇦🇺Camberwell, Victoria, Australia
UMHAT Kaspela EOOD /ID# 223141
🇧🇬Plovdiv, Bulgaria
UMHAT Sveti Ivan Rilski /ID# 223139
🇧🇬Sofia, Bulgaria
Hamilton Health Sciences - McMaster University Medical Centre /ID# 212662
🇨🇦Hamilton, Ontario, Canada
UMHAT Sveti Ivan Rilski /ID# 223140
🇧🇬Sofia, Bulgaria
Diex Recherche Sherbrooke Inc. /ID# 217734
🇨🇦Sherbrooke, Quebec, Canada
Peking Union Medical College Hospital /ID# 211614
🇨🇳Beijing, Beijing, China
Guangdong Provincial People's Hospital /ID# 211811
🇨🇳Guangzhou, Guangdong, China
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital /ID# 213694
🇯🇵Hiroshima-shi, Hiroshima, Japan
Hamanomachi Hospital /ID# 213696
🇯🇵Fukuoka-shi, Fukuoka, Japan
Yokohama Rosai Hospital /ID# 213690
🇯🇵Yokohama-shi, Kanagawa, Japan
EIRAKU Internal Medicine Clinic /ID# 215419
🇯🇵Kagoshima-shi, Kagoshima, Japan
Tohoku University Hospital /ID# 213693
🇯🇵Sendai-shi, Miyagi, Japan
KonKuk University Medical Center /ID# 213410
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Centro de Estudios de Investigación Básica y Clínica, S.C. /ID# 212532
🇲🇽Guadalajara, Jalisco, Mexico
Vrije Universiteit Medisch Centrum /ID# 214424
🇳🇱Amsterdam, Netherlands
Leids Universitair Medisch Centrum /ID# 214413
🇳🇱Leiden, Netherlands
Middlemore Clinical Trials /ID# 213504
🇳🇿Papatoetoe, Auckland, New Zealand
North Shore Hospital /ID# 213506
🇳🇿Takapuna, Auckland, New Zealand
Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o. /ID# 212146
🇵🇱Krakow, Malopolskie, Poland
Mindful Medical Research /ID# 213384
🇵🇷San Juan, Puerto Rico
Hospital Universitario y Politecnico La Fe /ID# 211720
🇪🇸Valencia, Spain
Cambridge University Hospitals NHS Foundation Trust /ID# 213189
🇬🇧Cambridge, United Kingdom
AZ Arthritis and Rheumotology Research, PLLC /ID# 211329
🇺🇸Phoenix, Arizona, United States
AZ Arthritis and Rheumotology Research, PLLC /ID# 214267
🇺🇸Phoenix, Arizona, United States
Arthritis & Osteo Medical Ctr /ID# 228235
🇺🇸La Palma, California, United States
East Bay Rheumatology Medical /ID# 211638
🇺🇸San Leandro, California, United States
University of Colorado Hospital /ID# 211314
🇺🇸Aurora, Colorado, United States
Yale University /ID# 212824
🇺🇸New Haven, Connecticut, United States
BayCare Medical Group, Inc. /ID# 218818
🇺🇸Tampa, Florida, United States
Henry Ford Health System /ID# 211676
🇺🇸Detroit, Michigan, United States
Tekton Research, Inc. /ID# 211521
🇺🇸Austin, Texas, United States
Tekton Research, Inc. /ID# 214182
🇺🇸Austin, Texas, United States